EVALUATION OF PROTEASE ACTIVATED RECEPTOR (PAR) ANTAGONISTS

蛋白酶激活受体 (PAR) 拮抗剂的评价

• 批准号: 7958547
• 负责人: Andras Gruber
• 金额: $ 8.03万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-04 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7958547
• 关键词: 2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole; Area; Computer Retrieval of Information on Scientific Projects Database; Disease; Evaluation; F2R gene; Funding; Grant; Hemostatic function; Institution; Primates; Proteinase-Activated Receptors; Research; Research Personnel; Research Project Grants; Resources; Source; Testing; Therapeutic; Thrombosis; United States National Institutes of Health; in vivo

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We continue our collaborative research with Bayer Corp. in areas of in thrombosis and hemostasis. We are engaged in a research project to generate definitive information whether PAR1 antagonists provided by Bayer have therapeutic potential for treatment of thromboembolic diseases. First, 5 compounds will be evaluated ex vivo, and 1 compound will be tested in vivo. Subsequently, 3 compounds will be evaluated ex vivo, and two compounds will be evaluated in vivo.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 我们继续与拜耳公司有关血栓形成和止血领域的合作研究。我们从事一个研究项目，以产生确定的信息，拜耳提供的PAR1拮抗剂是否具有治疗血栓栓塞疾病的治疗潜力。首先，将在体内评估5种化合物，并将在体内对1种化合物进行测试。随后，将在体内评估3种化合物，并将在体内评估两种化合物。